Pretransplant predictors of survival after intestinal transplantation: analysis of a single-center experience of more than 100 transplants.
BACKGROUND
Outcomes after intestinal transplantation (ITx) have steadily improved. There are few studies that assess factors associated with these enhanced results. The purpose of this study was to examine peri-ITx variables and survival.


METHODS
A review of a prospectively maintained database was undertaken and included all patients undergoing ITx from 1991 to 2010. The study endpoints were patient and graft survival. Data collection included 44 variables. Survival was computed using Kaplan-Meier methods. Univariate analysis was conducted (log-rank test) with significance set at P less than or equal to 0.20. Multivariate analysis of significant variables was conducted using model reduction by backward elimination variable selection method with significance set at P less than 0.05.


RESULTS
Eighty-eight patients received 106 ITx. The majority of recipients were male, Latino, and children. The leading causes of intestinal and liver failure were gastroschisis and parenteral nutrition. Grafts transplanted were isolated intestine (24%), liver-intestine (62%), and multivisceral (14%). Overall 1- and 5-year patient and graft survival were 80% and 65%, and 74% and 64%, respectively. Significant univariate survival predictors were weight less than 20 kg, children, liver-inclusive allograft, panel reactive antibody less than 20%, absence of donor-specific antibody, negative crossmatch, warm ischemia time less than 60 min, absence of recipient splenectomy, interleukin-2 receptor antagonist induction, and era. Significant multivariate survival predictors were absence of donor-specific antibody, absence of recipient splenectomy, and liver-inclusive graft type.


CONCLUSIONS
This large, single-center ITx experience confirms a marked improvement in outcome over time. Several important factors were associated with survival, and these factors can potentially be adjusted before ITx. These findings should refocus future efforts on strategies to improve treatment and prevent graft loss.
Department of Surgery, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA. dgfarmer@mednet.ucla.edu
Douglas G
DG
Farmer
Robert S
RS
Venick
Joanie
J
Colangelo
Yvonne
Y
Esmailian
Hasan
H
Yersiz
John P
JP
Duffy
Galen R
GR
Cortina
Kanela
K
Artavia
Khiet
K
Ngo
Suzanne V
SV
McDiarmid
Ronald W
RW
Busuttil
D002648:Child; D010122:Cystinyl Aminopeptidase / Q000235:genetics; D005260:Female; D006085:Graft Survival / Q000502:physiology; D006650:Histocompatibility Testing; D006801:Humans; D007422:Intestines / Q000637:transplantation*; D007518:Isoantibodies / Q000097:blood; D008297:Male; D057234:Preoperative Period; D011446:Prospective Studies; D013156:Splenectomy; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D007518:Isoantibodies; D010122:Cystinyl Aminopeptidase; C105964:leucyl-cystinyl aminopeptidase